

13th May, 2026

- | | |
|---|--|
| <p>(1) BSE Ltd
Listing Department
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai 400 001
Scrip Code: 500087</p> | <p>(2) National Stock Exchange of India Ltd
Listing Department
Exchange Plaza, 5th floor,
Plot no. C/1, G Block,
Bandra Kurla Complex,
Bandra (East), Mumbai - 400 051
Scrip Symbol: CIPLA</p> |
| <p>(3) SOCIETE DE LA BOURSE DE LUXEMBOURG
Societe Anonyme
35A Boulevard Joseph II,
L-1840 Luxembourg</p> | |

Sub: Investor Presentation

Dear Sir/Madam,

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith the Investor Presentation dated 13th May, 2026.

Kindly take the above information on record.

Thanking you,

Yours faithfully,
For **Cipla Limited**

RAJENDR
A CHOPRA

Digitally signed by
RAJENDRA CHOPRA
Date: 2026.05.13
12:56:47 +05'30'

Rajendra Chopra
Company Secretary

Encl: As above

Prepared by: Neelam Padwad

The Cipla logo is displayed in a bold, white, sans-serif font in the upper right corner of the slide. The background of the slide is a dark blue gradient with a white molecular structure pattern of hexagons and dots. A white diagonal line runs from the top center towards the bottom right, separating the background image from the blue patterned area.

Cipla

The text 'Investor Presentation' is written in a large, bold, white, sans-serif font, positioned in the lower left quadrant of the slide. It is overlaid on a background image of hands clasped together, which is faded and serves as the left side of the slide's background.

Investor Presentation

Q4FY26

13-05-2026

DISCLAIMER

Except for the historical information contained herein, statements in this presentation and the subsequent discussions may constitute "forward-looking statements". These forward-looking statements involve a number of risks, uncertainties, pandemic and other factors that could cause actual results to differ materially from those suggested by the forward-looking statements. These risks and uncertainties include, but are not limited to our ability to successfully implement our strategy, our growth and expansion plans, our ability to obtain regulatory approvals, technological changes, fluctuation in earnings, foreign exchange rates, our ability to manage international operations and exports, our exposure to market risks as well as other risks.

The investor presentation is not intended to endorse, advertise, promote or recommend the use of any products listed in it which are for representation purpose only, some of which are reference listed drugs of which the Company has approved, under approval or under development generic equivalents. The prefixes "g" and "generic" used interchangeably indicate the generic versions of the named brand drugs.

Information relating to any medical products or medical devices contained herein is provided by Cipla for general information purposes only. Information on any of the medical products or medical devices may vary from country-to-country. A reference to a medical product or a medical device does not imply that such medical product or medical device is available in your country. The commercial availability of the medical products or medical devices listed herein in your country is dependent on the validity and status of existing patents and/or marketing authorizations related to each. An independent enquiry regarding the availability of each medical products or medical device should be made for each individual country.





The product information contained herein is not intended to provide complete medical information, and is not intended to be used as an alternative to consulting with qualified doctors or health care professionals.

Nothing contained herein should be construed as giving of advice or the making of a recommendation and it should not be relied on as the basis for any decision or action. It is important to only rely on the advice of a health care professional.

Highest-ever Yearly Revenue; Despite Multiple Headwinds

	Revenue	EBITDA	PAT
Q4FY26	INR 6,541 Cr	INR 997 Cr (15.2% Margin)	INR 555 Cr (8.5% Margin)
FY26	INR 28,163 Cr	INR 5,925 Cr (21.0% Margin)	INR 3,879 Cr (13.8% Margin)

Business Performance Snapshot


	One India	North America	One Africa	Emerging Markets & Europe
Q4FY26	INR 3,007Cr  15% (YoY)	\$ 155 Mn	\$ 135 Mn  14% (YoY)	\$ 90 Mn
FY26	INR 12,680 Cr  9% (YoY) <i>Delivered double-digit growth across 3 segments in Q4 FY26</i>	\$ 780 Mn <i>Received approval for the first AB-rated gVentolin with CGT</i>	\$ 483 Mn  7% (YoY) <i>SA private growing at a market¹ growth multiple of 1.4x</i>	\$ 405 Mn <i>Crossed \$ 400 Mn benchmark</i>

1. Market data as per IQVIA MAT Feb'26

Financial Performance : Q4FY26

Revenues

INR 6,541 Cr



EBITDA

INR 997 Cr

Q4FY26 (Consolidated)

	Q4FY26 (INR Cr)	Q4FY25 (INR Cr)
Total Revenue from Operations	6,541	6,730
EBITDA	997	1,538
EBITDA %	15.2%	22.8%
PAT	555	1,222
PAT %	8.5%	18.2%


R&D² INR 509 Cr | 7.8% of revenue

1. One India includes Rx + Gx + CHL; One Africa includes South Africa, North Africa, Sub-Saharan Africa (SSA) and Cipla Global Access (CGA) | 2. Opex including depreciation

Financial Performance : FY26

Revenues

INR 28,163 Cr



EBITDA

INR 5,925 Cr

FY26 (Consolidated)





	FY 26 (INR Cr)	FY25 (INR Cr)
Total Revenue from Operations	28,163	27,548
EBITDA	5,925	7,128
EBITDA %	21.0%	25.9%
PAT	3,879	5,273
PAT %	13.8%	19.1%

R&D² INR 1,974 Cr | 7.0% of revenue

1. India includes Rx + Gx + CHL; One Africa includes South Africa, North Africa, Sub-Saharan Africa (SSA) and Cipla Global Access (CGA) | 2. Opex including depreciation

Strategic Focus Across Key Financial Metrics¹

INR Cr





1. FY23 and FY24 are Ex-QCIL

Strong Net-Cash : Assembling Resources to Fuel Growth Investments; \$ 1 Bn+ Net Cash Position in our Balance Sheet



INR Cr



1. Cash & cash equivalents includes current investments, fixed deposits, margin deposits and excluding unclaimed dividend balances

One India Business

FY26 Revenue INR 12,680 Cr

Q4FY26 Revenue

INR 3,007 Cr

Achieved robust double-digit growth across three segments



Branded Prescription

- ❖ Cipla maintained #2 rank in overall chronic with improved chronic mix² to 60.2%
- ❖ Launched key products like Voltido Trio Ciphaler, Huena, Zemdri, and Empacip during the year
- ❖ Double-digit growth² in chronic therapies like Respiratory, Urology, Anti-diabetes and Cardiac



Trade Generics

- ❖ Posted strong growth supported by robust performance across key categories
- ❖ 3 Brands with TTM revenue of > INR 100 Cr and 4 Brands with TTM revenue of INR 50 Cr to INR 100 Cr
- ❖ 17 new launches in FY26




Consumer Health

- ❖ Delivered a robust double-digit growth with anchor & transitioned brands continuing to grow bigger
- ❖ Sustained EBITDA margin trajectory
- ❖ Nicotex, Omnigel and Cipladine maintained their leadership positions in the market

India Branded Prescription¹ : Advancing with Strategic Precision

Double-Digit Growth in Key Therapies (%)



Rank

- 1st
- 2nd
- 11th
- 7th
- 11th

- Our in-house brand franchise, Dyltor, has scaled to over INR 650 Cr
- Foracort surpassed the INR 1,000 Cr milestone in IPM
- Respiratory supremacy, with Cipla's brands occupying all top 5 spots in the category

Key Market Highlights

Foracort
Biggest Respiratory Brand in the IPM

23 Brands
IPM Brands in Top 300 ranks

33 Brands
IPM Brands with revenue >INR 100 Cr

7 Therapies
With IPM Top 5 ranks

1. Market data as per IQVIA MAT Mar'26

Portfolio-Enhancing Introductions : Powering a Year of New Launches

Respiratory

Foracort G Synchronbreathe and Ciphaler




Enhancing adherence with intuitive device-led therapy for superior asthma & COPD control

voltido Trio 100 ciphaler®



Triple-action power for consistent bronchodilation & inflammation control in 1 device

AMR



A breakthrough for cUTI - effective beyond conventional choices

Cipenmet + Esblocip



Targeting resistant pathogens with a robust BL/BLI combination for critical infection

Urology



AMR in UTI - Non antibiotic prophylaxis management option for recurrent UTI


XTIKTR

— Regenerates Cells, Restores Flow —



Regenerative therapy addressing root causes to restore urinary function

Anti-diabetes




Comprehensive SGLT2-led portfolio enabling holistic glycemic management

Dermatology




Innovative therapy transforming hypertrophic scar management with improved patient outcomes


Key Strategic Transactions during the Year




Secured rights from Eli Lilly to distribute and promote Yurpeak® in India



Partnered with MannKind to launch India's only rapid acting inhaled insulin



Exclusive marketing and distribution rights for key brands (Corex, Dolonex, Neksium, Dalacin C)



Strengthened Neuro/CNS via acquisition of 3 brands to address neuropathic pain & sleep disorders



Launched Ciplostem, a DCGI-approved allogeneic MSC therapy for Knee Osteoarthritis



100% stake acquisition, adding a differentiated pediatrics & wellness portfolio



#1

India's Largest Trade Generic Business



5,500+ Stockiest Network
150,000+ Chemist coverage




15,000+ Pin codes serviced
400+ Retail field team (RTF)

Big Brands Bigger

3 Brands with Revenue > INR 100 Cr



4 Brands with Revenue INR 50 Cr - INR 100 Cr



Key New Launches



FY26 : Global Consumer Wellness Franchise

One India

OMNIGEL[®]

Pain Relief

nicotex

Smoking Cessation

**prolyte[™]
ORS**

Hydration

cofsils

Cold & Cough

CIPLADINE[®]

Skin Infection

Consumer Brands in One India

**FY26 Revenue :
INR 1,690 Cr**



Consumer Brands in South Africa

**FY26 Revenue :
ZAR 1,590 Mn**

One Africa

Cipla Actin

Respi OTC

CORYX

Cold and Cough

ASTHAVENT
Metered-dose inhaler

Respi OTC

accurate
pain - tension headache


Pain Management

BRONCOL

Cold and Cough

Key Generic Drug Approvals

gVentolin



**Liraglutide
(gSaxenda & gVictoza)**



Nintedanib



Dapagliflozin



Key Business Highlights



- Albuterol ranked No. 1 with total market¹ share at 19.6% (50 million+ inhaler units supplied to the U.S. market cumulatively)
- Received regulatory approval for the first AB-Rated gVentolin with CGT, representing the first commercial MDI product to be manufactured from our U.S. facility; launch is expected in coming months

1. Market data as per IQVIA MAT Mar'26



Pipeline Progress

Respiratory Pipeline

- 5 assets filed (4 assets expected commercialization in FY 27)
- 4 assets to be filed in next 24 months
- 2 assets to be filed with green propellant in next 24 months

Peptides & Complex Generics


- 8 assets filed (select launches expected in FY27-FY28)
- 3 assets to be filed in next 12 to 24 months

Oligo / 505(b)(2) Differentiated Products

- 3 505(b)(2) and 2 Oligonucleotide filed
- 1 Oligonucleotide & 2 505(b)(2) assets to be filed over next 12-18 months
- 2 Global Biosimilar assets - one in clinical study and one in early stage of development



ANDA & NDA Portfolio & Pipeline (As on 31st March 2026)





■ Cipla Ltd
 ■ PEPFAR¹
■ Invagen
 ■ Partnered ANDAs/NDAs

181 Approved ANDAs & NDAs	+	49 Tentatively Approved ANDAs & NDAs	+	55 Under Approval ANDAs & NDAs	=	285 Total ANDAs & NDAs
--	---	---	---	---	---	-------------------------------------

1. PEPFAR approved ANDAs can be commercialised in US

One Africa¹ : Continued Progress on Scaling-up Journey



Market Segment ²	Rank	Share	Cipla Growth	Market Growth
South Africa Prescription	2	8.8%	9.6%	6.1%
South Africa OTC	3	8.1%	1.2%	2.5%
South Africa Overall	3	8.5%	6.6%	4.8%

SA Key Highlights²

- Healthy performance across key therapies like Respiratory, CNS, Alimentary TR and Metabolism
- 9 brands with MAT revenue > 100 Mn ZAR
- Highest number of brands in top 30 (7), top 50 (11) and top 100 (21) within generics segment

1.4x Market² growth multiple

18 new launches
Across multiple therapies in FY26

1. One Africa includes South Africa, North Africa, Sub-Saharan Africa (SSA) and Cipla Global Access (CGA) | 2. Market data as per IQVIA MAT Feb'26

Progress on ESG goals (India Manufacturing Operations) : FY26

Goals (India Manufacturing Operations by 2025)	Progress : FY 2026
80% reduction in absolute Scope 1 (energy based) and Scope 2 emissions from baseline year of FY 2019-20	Achieved 83%* reduction from the baseline year, as on CY Dec 2025
Water neutrality	Achieved 2.6 times water positive
Zero Waste to Landfill ('ZWTL')	<ul style="list-style-type: none"> • All Cipla India Manufacturing operations are ZWTL re-certified • 24 units advanced from Platinum to Platinum+ certification • Additionally, 2 warehouses ZWTL certified—one domestic in Pune and one international, Cipla Distribution Gateway (CDG) in South Africa
50% renewable electricity	>50% renewable electricity achieved
Continuing zero fatality in our manufacturing operations	Achieved Zero Fatality
Full compliance with safe discharge targets established by AMR Industry Alliance	Achieved full compliance with the safe discharge targets Four AMR certified product – Azithromycin, Ofloxacin, Levofloxacin and Ciprofloxacin

Cipla (EU) Limited – Net Zero Commitment

- Cipla (EU) limited has committed to achieve net zero by 2050 and disclosed [Carbon Reduction Plan \(CRP\)](#).

Achievements and Recognition

- Cipla ranked by Business World as Top Sustainable Companies
 - 5th in the Healthcare and Pharma sector and
 - 46th among the top 60 companies, in India

*Emissions reduction data are currently under audit

Consolidated Profit and Loss Statement Summary (Reported)

INR Cr

Particulars	Q4 FY26	FY26
Revenue from sale of products	6,464	27,712
Other operating income	77	451
Income from operations	6,541	28,163
Material cost	2,249	9,549
Employee benefits expense	1,414	5,366
Other expenses	1,881	7,322
Total expenses	5,544	22,238
Finance costs	13	54
Depreciation, impairment and amortisation expense*	425	1,253
Other income	148	882
Profit before exceptional items and tax	707	5,500
Exceptional Items	-	276
Profit before tax	707	5,224
Tax expenses	157	1,354
Share of associate	-8	-8
Profit for the period	543	3,862
Non-controlling interest	-12	-17
Profit for the period attributable to shareholders	555	3,879

*Includes impairment of associates INR 42 Cr

Consolidated Balance Sheet Summary (Reported)

INR Cr

Cipla

Particulars	Mar-26	Mar-25
Net Tangible Assets	7,626	6,586
Goodwill & Intangibles	6,850	4,986
Investments	544	640
Other non-current assets	770	576
Advance tax assets (net)	568	411
Deferred tax assets (net)	748	591
Inventories	6,597	5,642
Cash and Cash Equivalents*	11,140	10,807
Trade receivable	5,620	5,506
Other Current Assets	1,873	1,471
Held for sale (net)	1	40
Total assets	42,377	37,257
Equity	34,432	31,193
Non-controlling interest	88	96
Borrowings	258	92
Lease Liabilities	356	346
Other non-current liabilities	269	159
Provisions	2,417	1,865
Trade Payable	3,230	2,837
Other liabilities	1,287	667
Total equity and liabilities	42,337	37,257

* Cash & cash equivalents include current investments, fixed deposits, margin deposits and excluding unclaimed dividend balances | Figures have been rounded off



Cipla

Thank You

Registered Office :

Cipla Limited, Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai 400 013

Diksha Maheshwari

Investor.Relations@cipla.com

For more information, please visit

www.cipla.com